Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy
- PMID: 21371602
- DOI: 10.1016/B978-0-12-381274-2.00018-2
Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy
Abstract
The application of NMR in fragment-based lead discovery (FBLD) has quickly developed from a sensitive method for the identification of low-affinity binders to an important tool in the hit-to-lead process. NMR can play a constructive role in the process from identifying those fragments with the best potential toward a biochemically active compound to developing them into molecules with high affinity and selectivity to a given target protein. NMR hit-to-lead involves revising the lead identification process at the beginning of a fragment-based drug discovery project, the primary screen, and also looking toward protein-detected NMR methods in advancing compounds from fragment hit into and through fragment hit-to-lead. With the development of higher sensitivity cold NMR probes, ligand-based NMR methods can be successfully applied to a majority of projects found in a pharmaceutical pipeline. Having matured from the original concepts such as SAR by NMR (Shuker, S. B., Hajduk, P. J., Meadows, R. P., Fesik, S. W. (1996) Discovering high-affinity ligands for proteins: SAR by NMR. Science274 (5292), 1531-1534.), projects that base their lead matter on fragment hits are close to or already in the clinic (Woodhead, A. J., Angove, H., Carr, M. G., Chessari, G., Congreve, M., Coyle, J. E., Cosme, J., Graham, B., Day, P. J., Downham, R., Fazal, L., Feltell, R., et al. (2010) discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J. Med. Chem.53, 5956-5969, Chessari, G., and Woodhead, A. J. (2009). From fragment to clinical candidate: A historical perspective. Drug Discov. Today14 (13-14), 668-675.). Generating new ideas toward new binding modes and mechanisms of action as well as new intellectual property will be the standard by which the success of FBLD will need to be measured. A strategy outlining the various steps involved in NMR hit-to-lead is provided. By means of a specific example, the workflow is described to guide the reader through the experimental setup.
Copyright © 2011 Elsevier Inc. All rights reserved.
Similar articles
-
Effective progression of nuclear magnetic resonance-detected fragment hits.Methods Enzymol. 2011;493:447-68. doi: 10.1016/B978-0-12-381274-2.00017-0. Methods Enzymol. 2011. PMID: 21371601
-
Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.J Biomol Screen. 2010 Sep;15(8):978-89. doi: 10.1177/1087057110375614. J Biomol Screen. 2010. PMID: 20817886
-
Practical aspects of NMR-based fragment screening.Methods Enzymol. 2011;493:219-39. doi: 10.1016/B978-0-12-381274-2.00009-1. Methods Enzymol. 2011. PMID: 21371593
-
Fragment-based ligand discovery.Mol Interv. 2009 Feb;9(1):22-30. doi: 10.1124/mi.9.1.7. Mol Interv. 2009. PMID: 19299661 Review.
-
Recent progress in fragment-based lead discovery.Curr Opin Pharmacol. 2009 Oct;9(5):615-21. doi: 10.1016/j.coph.2009.04.009. Epub 2009 May 27. Curr Opin Pharmacol. 2009. PMID: 19477685 Review.
Cited by
-
Targeting protein-protein interactions as an anticancer strategy.Trends Pharmacol Sci. 2013 Jul;34(7):393-400. doi: 10.1016/j.tips.2013.04.007. Epub 2013 May 29. Trends Pharmacol Sci. 2013. PMID: 23725674 Free PMC article. Review.
-
Medicinal chemistry for 2020.Future Med Chem. 2011 Oct;3(14):1765-86. doi: 10.4155/fmc.11.135. Future Med Chem. 2011. PMID: 22004084 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous